Market Place
Sourcing Support
Protagonist Reports Long Term Rusfertide Results At EHA2024 Congress
14 Jun 2024 //
ACCESSWIRE
Protagonist Presents Rusfertide Phase 2 REVIVE OLE Data At EHA 2024
14 May 2024 //
ACCESSWIRE
Protagonist Announces Closing of Worldwide Rusfertide License
18 Mar 2024 //
ACCESSWIRE
New England Journal of Medicine Publishes Results of Positive Ph 2 of Rusfertide
21 Feb 2024 //
ACCESSWIRE
Takeda and Protagonist Therapeutics, Inc. Enter into Agreement for Rusfertide
31 Jan 2024 //
ACCESSWIRE
Protagonist Announces Results from REVIVE Study of Rusfertide
15 Mar 2023 //
ACCESSWIRE
FDA seeks to pull Protagonist breakthrough nod over malignancies
15 Apr 2022 //
FIERCEBIOTECH
Protagonist posts hormone replacement data in iron disease
16 Nov 2021 //
PRNEWSWIRE
Protagonist Therapeutics Announces Updated Data from Phase 2 Study of Rusfertide
04 Nov 2021 //
PRNEWSWIRE
Eyes return to the prize for Protagonist’s rusfertide
12 Oct 2021 //
EVALUATE
Protagonist`s story gets a happy ending as FDA`s hold lifted
12 Oct 2021 //
ENDPTS
FDA lifts hold on Protagonist’s rusfertide clinical studies
11 Oct 2021 //
CLINICALTRIALSARENA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.